Nethradhama Super Speciality Eye Hospital, under the leadership of renowned ophthalmologist Prof. Dr. Sri Ganesh, has become the first hospital in Karnataka to launch Envision by InMode. This breakthrough, non-surgical technology provides a comprehensive dual solution: effectively treating the root cause of dry eye disease while simultaneously addressing cosmetic concerns around the eyes.
With screen time, pollution, and changing lifestyles at an all-time high, dry eye has become a rapidly growing issue across India. While conventional eye drops often provide only temporary, symptomatic relief, Envision stands out by directly treating factors such as meibomian gland dysfunction and eyelid inflammation. Powered by Forma-I technology, the treatment gently unblocks these glands to restore the eye's natural tear production. Furthermore, it utilizes Lumecca-I, the world’s leading Intense Pulsed Light (IPL) technology, to safely target and reduce the associated eyelid inflammation.
Designed for patient convenience, the Envision treatment goes beyond masking daily symptoms to deliver clinically proven, long-lasting relief. The sessions are quick and comfortable, taking only 10 to 12 minutes to complete, and require absolutely no downtime for recovery.
Developed by InMode, a recognized global leader in minimally invasive technologies, Envision brings world-class innovation to Karnataka. Alongside Forma-I and Lumecca-I for ocular health, InMode is globally renowned for pioneering devices like Morpheus8, an acclaimed treatment for addressing under-eye bags, droopy eyelids, surgical scars, and overall skin rejuvenation. Mr. Mohit Dawar, Head of the Ophthalmology Business at InMode India Pvt Ltd, noted that the launch of Envision at Nethradhama marks a critical milestone in expanding patient access to top-tier dry eye and ocular aesthetic treatments across the region.
Available Now At: Nethradhama Super Speciality Eye Hospital 256/14, Kanakapura Main Rd, 7th Block, Jayanagar, Bengaluru, Karnataka 560070 Website: www.nethradhama.org
No comments:
Post a Comment